Director · Spyre Therapeutics, Inc. · Common Stock
Side
J
Value
—
Shares
63.2K
Price
—
Executed
Jan 21, 2026
Disclosed
Jan 23, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 21 executedJan 23, 2026 disclosed
SYRE · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
No reported dollar value · 60.0% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Henderson Michael Thomas filed this Form 4 reporting a other acquisition or disposition of SYRE on Jan 21, 2026. It became public on Jan 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Henderson Michael Thomascik:0001779990
Issuer
Spyre Therapeutics, Inc.cik:0001636282
Revision history · 0
No field has changed since this record was first ingested.
